A股異動 | 四川路橋漲停 擬通過定增引入能投集團、比亞迪作為戰略投資者
格隆匯10月21日丨四川路橋(600039.SH)一字漲停,報9.28元,總市值443億人民幣。四川路橋昨日發佈公吿,擬發行股份及支付現金購買資產並配套募集資金,同時擬通過非公開發行股票引入能投集團、比亞迪作為戰略投資者參與本次發行股份的認購。公司擬以6.87元/股的價格向能投集團、比亞迪非公開發行股票,此次總共向特定對象發行數量不超過本次發行前公司股本總額的30%,募集資金總額約25億元。其中,擬向能投集團非公開發行7278.02萬股股票,擬向比亞迪非公開發行2911.21萬股股票。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.